Printer Friendly

Osiris Therapeutics reports preliminary Prochymal Phase III GvHD trials produce mixed results.

Osiris Therapeutics, Inc., Columbia, MD, announced that while preliminary results for two Phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD) showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, neither trial reached its primary endpoint.

The company says key findings from the trials include:

* There was no statistical difference between Prochymal and placebo on the primary endpoints for either the steroid-refractory (35% vs. 30%, n=260) or the first-line (45% vs. 46%, n=192) GvHD trials.

* The primary endpoint for the steroid-refractory GvHD trial (durable complete response) for the per-protocol population approached statistical significance (40% vs. 28%, p=087, n=179)

* In patients with steroid-refractory liver GvHD, treatment with Prochymal significantly improved response (76% vs. 47%, p=026, n=61) and durable complete response (29% vs. 5%, p=0.046)

* Prochymal significantly improved response rates in patients with steroid-refractory gastrointestinal GvHD (88% vs. 64%, p=018, n=71)

* In pediatric patients, Prochymal showed a strong trend of improvement in response rates (86% vs. 57%, p=0.094, n=28).

Osiris says the majority of patients in Protocol 265 were suffering from skin GvHD, which responded significantly better to steroids than had been previously reported in controlled trials which diminished the potential for Prochymal to demonstrate an effect.

In the more severe, steroid-refractory GvHD setting (Protocol 280), the benefit of adding Prochymal to second-line therapy was evaluated. The company reports Prochymal approached statistical significance for the primary endpoint in the per-protocol patient population, which is the group of patients that met all the study protocol requirements, such as inclusion and exclusion data. In addition, Prochymal significantly improved response rates to liver and gastrointestinal HvHD, for which there is no known reliable therapy.

Based on the results of the steroid-refractory GvHD trial, Osiris says it plans to file an amendment with the US Food and Drug Administration (FDA) to the current expanded access program, broadening the entry criteria to include patients with severe GvHD of the liver.

Contact: www.Osiris.com
COPYRIGHT 2009 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Date:Sep 1, 2009
Words:339
Previous Article:NATCO.
Next Article:Roche gets FDA to approval market Valcyte to prevent CMV in pediatric heart or kidney transplant patients.
Topics:


Related Articles
Osiris cleared by FDA to begin Phase II stem cell trial for the treatment of Crohn's Disease.
Osiris Therapeutics reports positive trial results using Prochymal in treatment-resistant Chrohn's Disease.
Osiris reports positive Phase II trial results using Prochymal for treatment of GVHD.
Osiris receives FDA ok to initiate Phase III pivotal trial for Prochymal as first line treatment for acute GVHD.
Osiris receives FDA fast track status for Prochymal in treat Crohn's disease; European approval for treating GVHD.
Osiris Therapeutics to get milestone payment from JCR Pharmaceuticals to start clinical trial in Japan.
Osiris completes enrollment in adult mesenchymal stem cell trial to treat pulmonary disease.
Osiris Therapeutics completes patient enrollment in first worldwide Phase III stem cell trial.
Osiris Therapeutics completes enrollment in 2nd Prochymal Phase III trial for acute graft vs. host disease.
Osiris enrolls first heart patient in Phase II stem cell trial; halts Phase III Crohn's study over concerns with trial design.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |